Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT05010005 Active, not recruiting - Clinical trials for T-cell Large Granular Lymphocyte Leukemia

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Start date: August 12, 2021
Phase: Phase 1
Study type: Interventional

This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma.

NCT ID: NCT05008224 Active, not recruiting - Clinical trials for Classical Hodgkin Lymphoma

Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

KEYNOTE-C11
Start date: October 7, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) monotherapy, followed by chemotherapy, followed by pembrolizumab consolidation. The primary hypothesis of the study is that the complete response (CR) rate at the end of study intervention according to Lugano 2014 response criteria is higher than conventional chemotherapy.

NCT ID: NCT05008055 Active, not recruiting - Clinical trials for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

CAPITAL
Start date: November 3, 2021
Phase: Phase 2
Study type: Interventional

This study is an open-label, multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL).

NCT ID: NCT05007652 Completed - Clinical trials for Multiple Myeloma and Malignant Lymphoma

A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma

Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

To determine if KRN125 is non-inferior to filgrastim for the mobilization of hematopoietic stem cells into the peripheral blood in patients with multiple myeloma.

NCT ID: NCT05006716 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Start date: September 13, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

NCT ID: NCT05006664 Not yet recruiting - Clinical trials for Lymphoma, T-Cell, Peripheral

Brentuximab Vedotin in Combination With CHEP in Patient With PTCL

Start date: October 2021
Phase: Phase 2
Study type: Interventional

A Phase II Open Label Study of Brentuximab Vedotin in Combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas (PTCL)

NCT ID: NCT05006534 Completed - Refractory Lymphoma Clinical Trials

Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell Lymphoma

Start date: June 1, 2020
Phase:
Study type: Observational

This study enrolled patients with relapsed or refractory diffuse large B cell lymphoma treated with polatuzumab vedotin-based chemoimmunotherapies. Patients were allowed to use chemotherapy regimens other than Rituximab and Bendamustine and transplantation following polatuzumab vedotin was also allowed.

NCT ID: NCT05004961 Recruiting - Clinical trials for Positron-Emission Tomography

The Performance of Multi-tracer Multimodality PET in Lymphoma

Start date: September 15, 2019
Phase:
Study type: Observational

Investigating the performance of Multi-tracer Multimodality PET in lymphoma

NCT ID: NCT05004064 Not yet recruiting - Clinical trials for Mantle Cell Lymphoma

Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma

CARAMEL
Start date: January 1, 2023
Phase: Phase 2
Study type: Interventional

This is a phase II, single-arm, open-label, multicentre study of acalabrutinib and rituximab for elderly or frail patients with previously untreated mantle cell lymphoma.

NCT ID: NCT05003141 Recruiting - Clinical trials for Mantle Cell Lymphoma

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Start date: November 15, 2021
Phase: Phase 1
Study type: Interventional

Product: PSB202 is a novel biological entity consisting of two engineered monoclonal antibodies, an Fc-enhanced humanized type II anti-CD20 IgG1 (PSB102) and a humanized anti-CD37 IgG1 (PSB107), that target B-cells. PSB202 is manufactured to work as a single product with the two components of PSB202 enabling a distinct dual target-specific antibody directed cell killing of B-cells. Study: Multi-center-, International Phase 1a/1b (Escalation/Expansion) study in patients with indolent-, relapsed-, B-cell malignancies. The Phase 1a (Dose Escalation) part of study follows a 3+3 design.